Telix Launches US$550M Convertible Bond Refinancing to Push Out 2029 Maturity
Telix launches US$550 million convertible bond offering to refinance 2029 notes
In its 14 April 2026 announcement, Telix Pharmaceuticals (ASX: TLX) has launched an offering of US$550 million in new convertible bonds due 2031 to refinance its existing convertible bonds maturing in 2029. The new bonds, to be issued through wholly-owned subsidiary Telix Pharmaceuticals (Investments) Inc., carry a coupon range of 1.50% – 1.75% and a conversion premium of 35.0% – 37.5% above the reference share price.
This is a refinancing transaction rather than a new capital raise. The net proceeds will be used to repurchase the existing 2029 convertible bonds through a concurrent reverse bookbuilding process, with any surplus funds directed to general corporate purposes. The bonds are non-dilutive to existing shareholders until any future conversions occur, as the conversion price will be set at a premium to the current share price.
Managing Director and Group CEO Dr Christian Behrenbruch highlighted the proactive capital management approach:
Dr Christian Behrenbruch, Managing Director and Group CEO
“The refinance of the existing Convertible Bonds represents our proactive approach to capital management. The new Convertible Bonds will continue to provide the business with cost effective financing.”
The bonds will be listed on the Official List of Singapore Exchange Securities Trading Limited (SGX-ST), with the final terms to be determined via a bookbuild process expected to complete prior to market open on 15 April 2026. J.P. Morgan Securities plc is acting as Sole Bookrunner on the offering and Sole Dealer Manager on the concurrent repurchase.
When big ASX news breaks, our subscribers know first
What are convertible bonds and why do companies use them?
Convertible bonds are debt instruments that can be converted into a company’s shares at a predetermined price, typically set at a premium to the current market price. In Telix’s case, the conversion premium of 35.0% – 37.5% means bondholders can only convert their debt into equity if the share price rises significantly above the reference price established at issuance.
The “non-dilutive until conversion” concept means existing shareholders face no immediate dilution of their ownership stake. Dilution only occurs if the share price appreciates enough to make conversion attractive to bondholders. This differs from a standard equity raising, which creates immediate dilution regardless of future share price movements.
Companies favour convertible bonds because they offer lower interest rates than traditional corporate debt. Investors accept lower coupon payments in exchange for the potential equity upside if the share price performs strongly. For Telix, refinancing existing debt at similar or improved terms extends the maturity runway while maintaining cost-effective financing, preserving financial flexibility for ongoing commercialisation activities.
The conversion premium also protects existing shareholders by ensuring conversions only occur at significantly higher share prices. This structure aligns the interests of bondholders with equity holders, as both benefit from strong share price performance.
Key terms of the new convertible bonds
The structured terms of the new convertible bonds provide a clear framework for investors and existing shareholders. A notable feature is the investor put option at the end of year 3, which allows bondholders to require early redemption if they choose not to hold to maturity.
The reference share price will be determined through a delta placement mechanism running concurrently with the offering. This delta placement facilitates hedging activity by investors and establishes the clearing price used to calculate the initial conversion price of the bonds.
| Term | Detail |
|---|---|
| Issuer | Telix Pharmaceuticals (Investments) Inc. |
| Guarantors | Telix Pharmaceuticals Limited and Telix Pharmaceuticals (US) Inc. |
| Expected Size | US$550 million |
| Maturity Date | 5 years (2031) |
| Investor Put Option | End of year 3 |
| Coupon / Yield | 1.50% – 1.75% |
| Conversion Premium | 35.0% – 37.5% |
| Reference Share Price | Clearing price of the Delta Placement |
| Ranking | Direct, unconditional, unsubordinated and unsecured obligations |
| Listing | SGX-ST |
| Selling Restrictions | Reg S (Category 2) only |
The bonds rank as direct, unconditional, unsubordinated and unsecured obligations of both the issuer and guarantors. Standard anti-dilutive adjustments apply, including conversion price adjustments for all dividends paid by Telix during the bond term.
The next major ASX story will hit our subscribers first
Transaction mechanics and timeline
The refinancing transaction involves several concurrent processes designed to ensure a clean transition from the existing 2029 bonds to the new 2031 facility. Understanding the sequence helps clarify how the various components interact.
-
New Bond Offering: Telix launches the US$550 million convertible bond offering through a bookbuild process managed by J.P. Morgan, targeting completion prior to market open on 15 April 2026.
-
Delta Placement: Concurrently, J.P. Morgan runs a bookbuilding process to facilitate some or all of the hedging activity that may be executed by investors in the Convertible Bonds. The clearing price per ordinary share under the delta placement becomes the reference share price for calculating the conversion price.
-
Concurrent Repurchase: Simultaneously, Telix conducts a reverse bookbuilding process to receive indications of interest from holders of the existing 2029 convertible bonds. The number of existing bonds repurchased and the purchase price will be determined through this process.
-
Stock Borrow Facility: To assist implementation, Elk River Holdings Pty Ltd as trustee for The Behrenbruch Family Trust (in which Dr Behrenbruch holds an indirect interest) has agreed to enter into a stock lending agreement with an affiliate of J.P. Morgan, providing ordinary shares to support the transaction mechanics.
-
Net Proceeds Application: After deduction of commissions, professional fees and administrative expenses, net proceeds will repurchase the existing 2029 convertible bonds. Any surplus funds will be applied to general corporate purposes.
The concurrent repurchase structure ensures Telix is not carrying duplicate debt facilities. By repurchasing the existing bonds as the new bonds settle, the company maintains its overall debt level while extending the maturity profile and potentially improving terms.
What this means for Telix shareholders
The refinancing outcome delivers extended debt maturity without immediate shareholder dilution, a material benefit for equity holders. By replacing 2029 bonds with 2031 bonds, Telix extends its debt maturity runway by approximately two years, providing greater financial flexibility to support commercialisation activities for its radiopharmaceutical pipeline.
The non-dilutive structure in the near term preserves equity value. Conversion can only occur if the share price appreciates significantly above the reference price (by 35.0% – 37.5%), meaning existing shareholders benefit from share price growth before any dilution materialises. This is a Regulation S offering targeting international investors only, not U.S. registered investors.
The maintained low-cost financing (coupon of 1.50% – 1.75%) compares favourably to traditional corporate debt rates, reducing Telix’s interest expense burden. This preserves cash flow for operational deployment rather than debt servicing costs, supporting the company’s ongoing product commercialisation and development programmes across its oncology and rare disease portfolio.
Want the Next Healthcare Winner in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with expert analysis. Get market-moving announcements delivered straight to your inbox the moment they drop. Click the “Free Alerts” button at Big News Blast to stay ahead on healthcare sector news.